• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新冠病毒加强疫苗在接受血液透析治疗的日本慢性肾脏病患者中诱导的T细胞反应和抗体产生

T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis.

作者信息

Yoshifuji Ayumi, Toda Masataro, Ryuzaki Munekazu, Oyama Emi, Kikuchi Kan, Kawai Toru, Sakai Ken, Koinuma Masayoshi, Katayama Kazuhiko, Yokoyama Takashi, Uehara Yuki, Ohmagari Norio, Kanno Yoshihiko, Kon Hirofumi, Shinoda Toshio, Takano Yaoko, Tanaka Junko, Hora Kazuhiko, Nakazawa Yasushi, Hasegawa Naoki, Hanafusa Norio, Hinoshita Fumihiko, Morikane Keita, Wakino Shu, Nakamoto Hidetomo, Takemoto Yoshiaki

机构信息

Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan.

Division of Nephrology, Department of Internal Medicine, Tokyo Saiseikai Central Hospital, Tokyo 108-0073, Japan.

出版信息

Vaccines (Basel). 2023 Mar 14;11(3):653. doi: 10.3390/vaccines11030653.

DOI:10.3390/vaccines11030653
PMID:36992238
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10057502/
Abstract

Humoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the booster vaccination. SARS-CoV-2 immunoglobulin (IgG) levels, neutralizing antibody titers, and the T-SPOT.COVID test (T-SPOT) were measured prior to, three weeks after, and three months after the booster administration. The HD group had significantly higher SARS-CoV-2 IgG levels and neutralizing antibody titers against the original strain at three weeks and three months after the booster vaccination compared to the control group, albeit the HD group had lower SARS-CoV-2 IgG levels and neutralizing antibody titers before the booster administration. Moreover, the HD group had significantly higher T-SPOT levels at all three time points compared to the control group. The HD group also had significantly higher local and systemic adverse reaction rates than the control group. By booster vaccination, HD patients could acquire more effective SARS-CoV-2-specific humoral and cellular immunity than the control group.

摘要

体液和细胞免疫反应对于理解严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗接种后的免疫反应至关重要。在此，我们评估了血液透析（HD）患者在加强疫苗接种后的这些反应。在加强疫苗接种前、接种后三周和三个月时测量了SARS-CoV-2免疫球蛋白（IgG）水平、中和抗体滴度以及T-SPOT.COVID检测（T-SPOT）。与对照组相比，HD组在加强疫苗接种后三周和三个月时针对原始毒株的SARS-CoV-2 IgG水平和中和抗体滴度显著更高，尽管HD组在加强疫苗接种前的SARS-CoV-2 IgG水平和中和抗体滴度较低。此外，HD组在所有三个时间点的T-SPOT水平均显著高于对照组。HD组的局部和全身不良反应发生率也显著高于对照组。通过加强疫苗接种，HD患者比对照组能获得更有效的SARS-CoV-2特异性体液和细胞免疫。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e118/10057502/d6cb1d1fbbc9/vaccines-11-00653-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e118/10057502/0e67f1642ccc/vaccines-11-00653-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e118/10057502/30e83c125dc9/vaccines-11-00653-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e118/10057502/a17304012643/vaccines-11-00653-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e118/10057502/d6cb1d1fbbc9/vaccines-11-00653-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e118/10057502/0e67f1642ccc/vaccines-11-00653-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e118/10057502/30e83c125dc9/vaccines-11-00653-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e118/10057502/a17304012643/vaccines-11-00653-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e118/10057502/d6cb1d1fbbc9/vaccines-11-00653-g004.jpg

相似文献

1
T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis.新冠病毒加强疫苗在接受血液透析治疗的日本慢性肾脏病患者中诱导的T细胞反应和抗体产生
Vaccines (Basel). 2023 Mar 14;11(3):653. doi: 10.3390/vaccines11030653.
2
Investigation for the efficacy of COVID-19 vaccine in Japanese CKD patients treated with hemodialysis.关于新型冠状病毒肺炎疫苗对接受血液透析治疗的日本慢性肾脏病患者疗效的调查。
Ren Replace Ther. 2022;8(1):39. doi: 10.1186/s41100-022-00427-2. Epub 2022 Aug 19.
3
Maintenance of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients after 1273-mRNA SARS-CoV-2 Vaccination.1273-mRNA型严重急性呼吸综合征冠状病毒2疫苗接种后长期血液透析患者有效细胞免疫和体液免疫反应的维持
Pharmaceuticals (Basel). 2023 Apr 11;16(4):574. doi: 10.3390/ph16040574.
4
Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G Levels After the Pfizer-BioNTech Booster Dose for Coronavirus Disease 2019 (COVID-19) Vaccination During the Second Trimester of Pregnancy.母体和新生儿 2019 年冠状病毒病（COVID-19）疫苗接种第二孕期接种辉瑞-生物技术公司 COVID-19 疫苗加强针后严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）免疫球蛋白 G 水平。
Obstet Gynecol. 2022 Aug 1;140(2):187-193. doi: 10.1097/AOG.0000000000004867. Epub 2022 May 27.
5
T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents.养老院居民中初次接种和加强接种 SARS-CoV-2 信使 RNA 疫苗后的 T 细胞介导的反应。
J Am Med Dir Assoc. 2023 Feb;24(2):140-147.e2. doi: 10.1016/j.jamda.2022.11.024. Epub 2022 Dec 7.
6
Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination.1273-mRNA 新冠病毒疫苗接种后长期血液透析患者中产生强烈细胞和体液免疫应答。
Front Immunol. 2022 Mar 23;13:845882. doi: 10.3389/fimmu.2022.845882. eCollection 2022.
7
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.抗肿瘤治疗的癌症患者接种 BNT162b2 冠状病毒病 2019 信使 RNA 疫苗后体液免疫应答降低。
ESMO Open. 2021 Oct;6(5):100274. doi: 10.1016/j.esmoop.2021.100274. Epub 2021 Sep 8.
8
Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study.两剂标准剂量疫苗接种后新型冠状病毒2中和抗体的演变、无应答的危险因素以及第三剂加强疫苗对血液透析无应答者的影响：一项前瞻性多中心队列研究
J Clin Med. 2021 Oct 30;10(21):5113. doi: 10.3390/jcm10215113.
9
Diminished and waning immunity to COVID-19 vaccination among hemodialysis patients in Israel: the case for a third vaccine dose.以色列血液透析患者对新冠疫苗接种的免疫力减弱和逐渐消退：关于第三剂疫苗的情况
Clin Kidney J. 2021 Oct 12;15(2):226-234. doi: 10.1093/ckj/sfab206. eCollection 2022 Feb.
10
Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study.基于mRNA的第三剂和第四剂加强疫苗接种对慢性血液透析患者中SARS-CoV-2中和抗体滴度形成、无应答危险因素及SARS-CoV-2奥密克戎突破性感染后结局的影响：一项前瞻性多中心队列研究
J Clin Med. 2022 Jun 2;11(11):3187. doi: 10.3390/jcm11113187.

引用本文的文献

1
Group of longitudinal adverse event patterns after the fourth dose of COVID-19 vaccination with a latent class analysis.第四剂 COVID-19 疫苗接种后纵向不良事件模式的潜伏类分析。
Front Public Health. 2024 Jul 30;12:1406315. doi: 10.3389/fpubh.2024.1406315. eCollection 2024.
2
Humoral and cellular immunity against different SARS-CoV-2 variants in patients with chronic kidney disease.慢性肾脏病患者针对不同 SARS-CoV-2 变体的体液和细胞免疫。
Sci Rep. 2023 Nov 15;13(1):19932. doi: 10.1038/s41598-023-47130-8.

本文引用的文献

1
Investigation for the efficacy of COVID-19 vaccine in Japanese CKD patients treated with hemodialysis.关于新型冠状病毒肺炎疫苗对接受血液透析治疗的日本慢性肾脏病患者疗效的调查。
Ren Replace Ther. 2022;8(1):39. doi: 10.1186/s41100-022-00427-2. Epub 2022 Aug 19.
2
Robust antibody response after a third BNT162b2 vaccine compared to the second among immunocompromised and healthy individuals, a prospective longitudinal cohort study.免疫功能低下和健康个体中，第三剂 BNT162b2 疫苗接种后产生的抗体反应强于第二剂，一项前瞻性纵向队列研究。
Vaccine. 2022 Jun 26;40(30):4038-4045. doi: 10.1016/j.vaccine.2022.05.051. Epub 2022 May 28.
3
SARS-CoV-2 Antibody and T Cell Response after a Third Vaccine Dose in Hemodialysis Patients Compared with Healthy Controls.
血液透析患者与健康对照者接种第三剂疫苗后的新冠病毒抗体和T细胞反应
Vaccines (Basel). 2022 Apr 28;10(5):694. doi: 10.3390/vaccines10050694.
4
Immunogenicity of ChAdOx1 nCoV-19 vaccine after a two-dose inactivated SARS-CoV-2 vaccination of dialysis patients and kidney transplant recipients.两剂灭活 SARS-CoV-2 疫苗接种后，ChAdOx1 nCoV-19 疫苗在透析患者和肾移植受者中的免疫原性。
Sci Rep. 2022 Mar 4;12(1):3587. doi: 10.1038/s41598-022-07574-w.
5
The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals.SARS-CoV-2 病毒 E484K 突变对 BNT162b2 疫苗接种个体的抗体中和活性的影响。
Vaccine. 2022 Mar 18;40(13):1928-1931. doi: 10.1016/j.vaccine.2022.02.047. Epub 2022 Feb 14.
6
Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.第二剂 BNT162b2 新冠疫苗接种后反应原性与 SARS-CoV-2 抗体的相关性。
Vaccine. 2022 Mar 18;40(13):1924-1927. doi: 10.1016/j.vaccine.2022.02.052. Epub 2022 Feb 14.
7
Factors associated with SARS-CoV-2 antibody titers and prognosis of breakthrough infection in hemodialysis patients.与 SARS-CoV-2 抗体滴度和血液透析患者突破感染预后相关的因素。
Clin Exp Nephrol. 2022 Jun;26(6):571-580. doi: 10.1007/s10157-022-02188-y. Epub 2022 Feb 8.
8
The T cell immune response against SARS-CoV-2.针对 SARS-CoV-2 的 T 细胞免疫应答。
Nat Immunol. 2022 Feb;23(2):186-193. doi: 10.1038/s41590-021-01122-w. Epub 2022 Feb 1.
9
Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks.腹膜透析和血液透析患者接种新冠疫苗后12周的纵向体液反应
Vaccines (Basel). 2021 Oct 4;9(10):1130. doi: 10.3390/vaccines9101130.
10
Performance of the T-SPOT.COVID test for detecting SARS-CoV-2-responsive T cells.T-SPOT.COVID 试验检测 SARS-CoV-2 反应性 T 细胞的性能。
Int J Infect Dis. 2021 Dec;113:155-161. doi: 10.1016/j.ijid.2021.09.073. Epub 2021 Sep 30.